Lusutrombopag 在有或无肝细胞癌患者中治疗血小板减少安全有效
该研究整合两项 3 期试验(L-PLUS 1 和 L-PLUS 2),比较 lusutrombopag 与安慰剂在慢性肝病伴或不伴肝细胞癌(HCC)患者中的疗效与安全性。主要终点为侵入性操作前无需血小板输注且操作后 7 天内无需针对出血的抢救治疗;伴 HCC 患者中 lusutrombopag 组达标率 68.0% 对安慰剂组 8.9%(P < .0001),不伴 HCC 患者中为 77.0% 对 21.6%(P < .0001)。
要点
- 伴 HCC 患者中 lusutrombopag 主要终点达标率 68.0%,安慰剂组 8.9%(P < .0001)。
- 不伴 HCC 患者中达标率 77.0% 对 21.6%(P < .0001)。
- lusutrombopag 减少血小板输注需求、提升血小板计数 3 周并减少出血事件,血栓风险与安慰剂相似。
核心结论
- 在伴或不伴 HCC 的慢性肝病血小板减少患者中,lusutrombopag 较安慰剂减少侵入性操作前的血小板输注,且未增加血栓或出血风险。
研究设计与样本
- 整合分析两项 3 期试验(L-PLUS 1 日本,2013 年 10 月至 2014 年 5 月;L-PLUS 2 全球,2015 年 6 月至 2017 年 4 月),比较 lusutrombopag 与安慰剂。
- 纳入 ECOG 评分 0 或 1、Child-Pugh A 或 B 级、血小板计数低于 50 × 10^9/L 且计划 9 至 14 天内接受侵入性操作的患者。
- 患者接受 lusutrombopag 3 mg 或安慰剂每日一次,最多 7 天,直至侵入性操作前。
- 符合方案人群共 270 例患者,其中 95 例伴 HCC。
主要发现
- 伴 HCC 患者中,lusutrombopag 组主要终点达标率 68.0%,安慰剂组 8.9%(P < .0001)。
- 不伴 HCC 患者中,lusutrombopag 组主要终点达标率 77.0%,安慰剂组 21.6%(P < .0001)。
- 与安慰剂相比,lusutrombopag 减少伴或不伴 HCC 患者的血小板输注需求、提升血小板计数达 3 周并减少出血事件。
- 血栓风险与安慰剂相似。
关键数值与推荐
- 主要终点定义为侵入性操作前无需血小板输注且操作后 7 天内无需针对出血的抢救治疗。
- 纳入标准包括血小板计数低于 50 × 10^9/L、ECOG 评分 0 或 1、Child-Pugh A 或 B 级。
- lusutrombopag 用法为 3 mg 每日一次,最多 7 天。
临床怎么用
- 对于伴或不伴 HCC 的慢性肝病血小板减少患者,lusutrombopag 可考虑用于侵入性操作前提升血小板、减少输注需求。
- 使用中需关注血栓风险,但本分析显示与安慰剂相似。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Patients with hepatocellular carcinoma (HCC) secondary to chronic liver disease often require invasive procedures but frequently have thrombocytopenia. Lusutrombopag is an agonist of the thrombopoietin receptor that activates platelet production. METHODS: We performed an integrated analysis of data from 2 phase 3 trials (L-PLUS 1, Japan, October 2013 to May 2014, and L-PLUS 2, global, June 2015 to April 2017) that compared the efficacy and safety of lusutrombopag with placebo in patients with chronic liver disease, with and without HCC. Our analysis included patients with Eastern Cooperative Oncology Group grades of 0 or 1, Child-Pugh classes A or B, and a platelet count less than 50 × 109/L who were scheduled to undergo invasive procedures in 9 to 14 days. Patients received lusutrombopag (3 mg) or placebo daily for 7 days or fewer before an invasive procedure. Imaging studies assessed treatment-emergent adverse events, including asymptomatic portal vein thrombosis. The primary end point was no requirement for platelet transfusion before the invasive procedure and rescue therapies for bleeding 7 days or fewer after the invasive procedure. RESULTS: The per-protocol population included 270 patients (95 with HCC). A significantly higher proportion of patients with HCC who received lusutrombopag achieved the primary end point (68.0%) vs patients who received placebo (8.9%) (P < .0001); in patients without HCC, these proportions were 77.0% vs 21.6% (P < .0001). Lusutrombopag reduced the need for platelet transfusions, increased platelet counts for 3 weeks, and reduced the number of bleeding events in patients with and without HCC compared with placebo. Risk of thrombosis was similar to that of placebo. CONCLUSIONS: Patients with and without HCC receiving lusutrombopag had a reduction in the number of platelet transfusions before invasive procedures compared with patients receiving placebo, with no increase in thrombosis or bleeding. L-PLUS 1: JapicCTI-132323; L-PLUS 2: ClinicalTrials.gov number no: NCT02389621.
引用
- Alkhouri N, Imawari M, Izumi N, et al. Lusutrombopag Is Safe and Efficacious for Treatment of Thrombocytopenia in Patients With and Without Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2020. PMID: 32205226. doi:10.1016/j.cgh.2020.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。